D. Strumberg Et Al. , "Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)," 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.31, Illinois, United States Of America, 2013
Strumberg, D. Et Al. 2013. Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC). 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).
Strumberg, D., Schultheis, B., Ebert, M. P., Kerkhoff, A., Hofheinz, R. D., Behringer, D. M., ... Schmidt, W. E.(2013). Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC) . 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America
Strumberg, Dirk Et Al. "Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)," 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2013
Strumberg, Dirk Et Al. "Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2013
Strumberg, D. Et Al. (2013) . "Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Dirk Strumberg Et Al. }, title={Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)}, congress name={49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2013}}